RxDoctor Payments Data

Steven Atkinson, PA

Medical · Minneapolis, MNNPI 1285614735

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,100 of the $2,448 with a category attached, or 85.8%. Pfizer accounts for 85.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $2,148 and has fallen 96.7% since, to $70 in 2023. Among medical clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,448in general payments, 2019–2025

Across 7 payments — averaging $349.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AstraZeneca$105
  • Acadia Pharmaceuticals Inc$93
  • CMP Pharma, Inc.$79
  • Neurocrine Biosciences, Inc.$50
  • Globus Medical$20

What the payments were for

  • Speaking & faculty fees$2,10086%
  • Food & beverage$34814%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$2,100
AstraZeneca1$105
Acadia Pharmaceuticals Inc2$93
CMP Pharma, Inc.1$79
Neurocrine Biosciences, Inc.1$50
Globus Medical1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,448 in reported general payments places this provider in the 90th percentile of 202 medical providers in Minnesota.

See all medical providers in Minnesota

Medicare billing

Part B allowed, 2024
$244,960
Medicare patients
346
Services billed
2,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban553$303,546
TrulicityDulaglutide139$141,760
JardianceEmpagliflozin172$81,407
XareltoRivaroxaban167$80,221
NuplazidPimavanserin Tartrate15$68,926
OzempicSemaglutide64$63,644
XifaxanRifaximin20$62,236
MyrbetriqMirabegron167$61,545
Invega SustennaPaliperidone Palmitate12$43,749
JanuviaSitagliptin Phosphate70$36,617
RybelsusSemaglutide38$36,123
Atorvastatin Calcium1,918$28,150
Breo ElliptaFluticasone/Vilanterol54$23,319
Duloxetine Hcl640$22,411
Lantus SolostarInsulin Glargine,hum.Rec.Anlog304$21,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$2,100$317,118597 claims
Acadia Pharmaceuticals IncNuplazid$93$68,92615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 202 medical providers in Minnesota.

Other medical in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →